The brief

Analyst view

• $365/year: 160+ tests twice yearly (heart, hormones, liver, kidney, inflammation, 1000+ conditions).
• 200K+ members, 100M+ tests since 2023 public launch. Optional preventive MRI and CT screening add-ons.
• Series B: $298M at $2.5B (Nov 2025, Redpoint lead); $450M growth capital (Jul 2026, General Catalyst).

Technical approach

As reported

Frequency

Twice-yearly testing

160+ tests semi-annually (not annual); creates trend data vs annual check-ups.

Breadth

160+ tests in one panel

One order: hormones, metabolics, inflammation, autoimmunity, nutrients, toxins, organ function.

Optional imaging

Whole-body MRI and CT

Add-on preventive imaging for early cancers and structural disease; partner centers.

Data interpretation

AI chat and clinical review

Private AI chat (built with clinicians) answers questions, finds patterns, next steps.

Show all 4